The National Health Council represents nearly 200 member organizations, with patient groups required by its bylaws to hold the majority of governance and decision-making roles. Five years after taking the helm as CEO, Randall “Randy” Rutta oversees an association formed more than a century ago to ensure the patient experience guides federal healthcare policy. In this interview, Rutta discusses navigating recent federal Medicaid and Medicare changes, the impact of drug price negotiation on biopharmaceutical investment, and the council’s work to give patient groups a direct voice in the deployment of healthcare AI.

 

Could you start by introducing yourself, the National Health Council (NHC), and its guiding purpose.

I have been involved in healthcare on both health policy and health service delivery throughout my entire career, with a focus on supporting individuals who are vulnerable due to chronic conditions, disabilities, complex health needs, and aging, as well as veterans with ongoing military-related issues. I have always been involved in organizations connected to the National Health Council (NHC). Five years ago, when former NHC CEO, Marc Boutin, moved on, the board asked me to step into this role. It was a very natural transition, like taking a different seat at the table for an organization I had long been part of.

The NHC is over 100 years old and was founded to ensure patients have a voice in decisions affecting their health and that the patient experience is considered by policymakers and healthcare decision-makers. Our guiding principle is always to ask how patients are currently affected and how decisions can improve their experience, effectiveness, efficiency, and welcome within the system.

We currently have just shy of 200 member organizations. By design of our bylaws, the majority must be patient organizations, which keeps patient groups at the center of our decision-making, policy development, and governance. Out of that membership, about 140 are patient organizations, and that number continues to grow. We also bring in other healthcare stakeholders so that their collective expertise helps inform our responses to policymakers and industry, while remaining focused on interpreting how these dynamics impact individual, societal, and population health.

 

Beyond patient groups what other member organizations does the NHC bring to the table?

Beyond patient organizations, which include everything from large groups like the American Heart Association and the American Lung Association to rare disease and smaller groups, we have a category called “partners of patients.” This group includes clinicians, nurses, doctors, pharmacy groups, researchers, and academics dedicated to patient-centered care such as the American Medical Association.

We also engage business and industry under the shared mission of serving patients effectively. Our membership includes biopharmaceutical companies, medical device associations and manufacturers, technology companies, and health insurers such as America’s Health Insurance Plans (AHIP) and individual insurance companies, as well as Amazon Health. Bringing these diverse perspectives together allows us to evaluate where the system is working, reinforce those areas, and identify where improvements are needed to elevate the patient experience.

 

With the many changes in policy and priorities that have come about under the second Trump administration, what is the overall stakeholder sentiment from where you sit as all of these changes land at the same time?

The word I would use is energized. The patient community is leaning into opportunities to help build a better system centered around access, affordability, and supporting and benefiting from the innovation pipeline. In the US healthcare system, with its mix of public and private models, access is the number one priority, and it is looming large right now.

The patient community has long recognized that the status quo was not benefiting patients as much as it should and that real opportunity for change existed. When the second term for President Trump began about a year and a half ago, kicking off a rapid and expansive view of change, it was initially concerning. Our healthcare system was built on decades of incremental progress, and while there were clear areas for improvement, there was also an attachment to what we knew versus what we did not.

A year and a half ago, the patient community was reeling from the extent to which the new administration called for sweeping changes to federal healthcare institutions, as well as its focus on waste, fraud, and abuse through a national security lens. It was a bit of “shock and awe” initially, but the patient community’s response was not to oppose change. Rather, there was a desire to understand the proposed pathways and ensure the best decisions were being made.

 

What does the NHC consider to be at the top of priority list when it comes to patient concerns across the American healthcare ecosystem?

There is currently an overemphasis on drug pricing relative to where the US healthcare dollar is actually spent. No part of the healthcare ecosystem matters more to patients than discovery and innovation. Having treatments that are curative or near-curative profoundly impacts patient quality of life, length of life, and the ability to work and support a family. Yet this reality is often overlooked in conversations around drug pricing. Too many policy decisions are driven strictly by 12-month cost savings or short-term 10-year budget windows used by the Congressional Budget Office (CBO), rather than evaluating health across a patient’s entire lifespan.

We need to shine a light on other areas of the healthcare system where significant dollars are expended without necessarily yielding better patient outcomes. Moreover, pulling resources away from the biopharmaceutical sector, whether through hospital dynamics under the 340B program or other cost shifts, directly impacts patients. 90 percent of patients do not have a targeted therapy specific to their condition or rely on older medications that desperately need further investment and innovation. Diverting funds from R&D ultimately diminishes the quality of life for patients both today and in the future.

 

Where did patient concerns fall regarding the Inflation Reduction Act (IRA), and how does the NHC view the balance of supporting cost-capping measures with protecting access to innovation while navigating policies like Most Favored Nation pricing and tariffs?

The National Health Council was very active during the crafting, passage, and interpretation of the Inflation Reduction Act (IRA). It was a chaotic process, but because the legislation included provisions our patient organizations had championed for years such as capping Part D out-of-pocket spending for Medicare beneficiaries, it was impossible for the patient community to simply oppose the bill outright.

At the same time, we took to heart industry concerns regarding the unintended consequences of drug price negotiations. Singling out specific Medicare drugs for price controls using frameworks reminiscent of foreign cost-effectiveness reviews like NICE or ICER risks signaling to companies that certain investments are no longer viable. We have seen company behavior shift in response. While natural clinical shifts toward rare diseases, oncology, and neurodegenerative conditions are occurring, there was real concern that the IRA’s negotiation framework would overly influence those R&D decisions, and some of those fears have been borne out.

Our primary contribution has been ensuring patients have a seat at the table. Although patient inclusion had a rocky start, the NHC emerged as a key partner and convener with CMS. We bring together affected patient groups throughout the year to help them understand how to participate in the negotiation process effectively and submit impactful input. CMS has taken our recommendations to heart and adapted its negotiation strategies to incorporate patient perspectives. The challenge is ensuring that policy evaluations are not driven solely by financial line items or short-term cost savings but instead consider what a medication means holistically to a patient’s ability to live, work, and care for their family.

That same philosophy applies to Most Favored Nation (MFN) pricing models and tariffs. I have spoken out strongly against MFN pricing because it is a flawed approach. Importing price controls from foreign healthcare systems that function entirely differently from the US will not serve American patients well. For instance, they often rely on discriminatory metric calculations like Quality-Adjusted Life Years (QALYs) that devalue patient lives. If we want to reform the US system, we should focus on the US system while learning from international best practices, rather than simply adopting foreign price caps.

Similarly, tariffs pose significant risks to patients. While building national capacity to manufacture and distribute medicines is a positive goal, healthcare and pharmaceutical innovation are global endeavors. Arbitrarily attaching costs or erecting trade barriers causes supply chain disruptions and immense anxiety for patients who rely on those products daily, especially in the medical device and supply sectors. We must ensure that policies preserve the long-term availability of treatments and medical products for the families who depend on them.

 

Beyond drug pricing, what key aspects of the broader healthcare system have the greatest impact on patients, and where are structural changes most urgently needed?

Healthcare spending is often viewed myopically through the lens of saving system costs rather than driving affordability for patients. While patients care deeply about resource efficiency and the overall sustainability of the healthcare system the overarching challenge is systemic complexity.

We have 21st-century medical innovations that sounded like science fiction not long ago, yet they operate within a post-World War II, early-1960s healthcare structure that we continue to patch together. It has become overly complex and transactional.

For example, in our work with insurers, we frequently address utilization management and prior authorization, which are labor-intensive and fundamentally flawed processes. If a patient, their family, and their physician determine the best course of treatment using an FDA-approved medicine, why is there so much external intervention? Frequently, these barriers seem designed to delay or avoid payment rather than optimize outcomes. Patients with autoimmune conditions, for instance, often wait three to seven years just to get a proper diagnosis. Once they finally have access to medicines that can help manage their condition, unnecessary systemic hurdles should not stand in their way.

 

What does the restructuring of Medicaid and Medicare actually mean for patients in practice, particularly regarding efforts to target waste, fraud, and abuse?

Regarding Medicaid, the patient community certainly supports eliminating true waste, fraud, and abuse and ensuring accurate program application. However, the core issue is how these measures are defined and implemented without denying legitimate patients access to essential services.

Legislative approaches like H.R. 1 (the One Big Beautiful Bill Act) approached these reforms primarily to drive cost savings. By establishing stringent administrative hurdles, the law relies on the expectation that many individuals will simply drop off the rolls. Historical experience shows that such bureaucratic requirements disproportionately harm eligible individuals. This is particularly the case for people with chronic conditions and disabilities who already face significant daily health, mobility, and accessibility challenges. Consequently, tens of millions of qualified individuals risk losing coverage.

Because much of this administrative burden falls on state governments, we are working closely with local partners and participating in meetings with groups like the National Conference of State Legislatures (NCSL). Our goal is to ensure constituents understand these requirements and to support state leaders who are feeling overwhelmed by shifting federal responsibilities.

Moreover, as federal financing mechanisms and state funding pathways are restricted, states face shrinking budgets to manage these programs. As a result, we are already seeing states curtail optional Medicaid services, such as home and community-based care, which are critical to helping individuals live, work, and stay healthy in their homes. States are being forced to cut these vital supports just to fund the extra bureaucratic requirements imposed by federal rules.

 

Where do you see the greatest opportunities for AI to advance patient access and outcomes, and how is the NHC ensuring that patient interests remain central as technology rapidly evolves?

AI has significant potential to streamline healthcare processes and refocus the system around the patient, but we will not endorse technology if it merely accelerates the flawed parts of our existing system.

To address this, we launched a dedicated initiative called the Patient Experience and Innovation (PXI) Center which now brings together more than 200 groups to share information and foster collaboration. Tech companies are often oriented toward business-to-business models and are not always best positioned to engage end consumers directly. Our board recognized two clear needs. First, to ensure the patient voice is considered at every level of AI design and deployment, and second, to equip resource-constrained patient organizations with the knowledge required to utilize these tools effectively while protecting patients.

The PXI Center makes the patient community visible and accessible to the technology sector, enabling patient advocates to sit at the table with tech decision-makers and speak their language fluently. We have seen a rapid adoption of AI expertise across our membership. A few years ago, organizations were asking about basic concepts like generative AI, and today, they are developing AI agents and integrating machine learning into patient registries to make more sophisticated use of their data. That progress is truly exciting.

 

Looking forward, what are the top priorities and key structural elements that must be addressed to ensure the healthcare system remains sustainable and truly centered on patients?

First and foremost, decision-makers must keep what is best for a patient over their entire lifetime top of mind, recognizing that patients are equal partners in drug discovery, clinical adherence, and utilization. We must identify and dismantle barriers across the system that impede investment in innovation. We have never been better positioned to transform care through scientific discovery, so any policy that hinders investment and access must be critically examined.

Second, we must maintain a strong, well-staffed FDA to ensure timely approvals of safe and effective treatments. Recent workforce disruptions and staffing changes across federal health agencies under this administration remain a significant concern for patients. Once the FDA deems an intervention safe and effective, we must close the long, unnecessary gap between regulatory approval and payer coverage and access. Payers should not exercise arbitrary discretion to delay treatments. Their role should be managing resources effectively to achieve the best health outcomes for patients and populations.

Third, for biopharmaceuticals and the broader innovation sector, we must eliminate needless systemic complexity. Patient organizations stand ready to support clinical trial recruitment, advocate to investors, and drive uptake when new treatments reach the market.

Finally, we need greater transparency and scrutiny across other, larger areas of healthcare spending. Spending on biopharmaceutical innovation has remained remarkably consistent for decades at roughly 9 to 11 percent of total US healthcare expenditure. We must ensure that the remaining 90 percent of the healthcare spend is held accountable, operates transparently, and does not drain resources away from life-saving discovery and patient access. This is an incredibly exciting era for medicine, and by working together, we can overcome the structural obstacles standing in the way of better health.